Highbridge Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Highbridge Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-30,700	Closed	-$226K	–	2121
2017 Q3	$226K	Sell	30,700 -51,600	-63%	-$328K	﹤0.01%	1360
2017 Q2	$558K	Buy	+82,300	New	+$608K	0.01%	724
2015 Q4	–	Sell	-67,600	Closed	-$387K	–	1941
2015 Q3	$387K	Buy	67,600 +35,700	+112%	+$274K	0.01%	1139
2015 Q2	$238K	Buy	+31,900	New	+$193K	﹤0.01%	1224

Other funds holding PGNX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

PFC

Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

Highbridge Capital Management's PGNX Position: Q4 2016 in Review

Highbridge Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2016, closing a stake of 63,548 shares — an estimated $402K sold.

Highbridge Capital Management first reported a position in PGNX in Q2 2013 and held it in 7 quarters. The position peaked at $1.34M in Q3 2013. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

Highbridge Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
Highbridge Capital Management sold 63,548 Progenics Pharmaceuticals Inc shares in Q4 2016, an estimated $402K.
Highbridge Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 7 quarters.
Highbridge Capital Management's Progenics Pharmaceuticals Inc position peaked at $1.34M in Q3 2013.
126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.